MedTrace Logo

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

NCT00940407 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-11-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on patients with dry Age Related Macular Degeneration (AMD).

Photobiomodulation is the use of non thermal, non laser light of specific wavelengths and energy directly on the eye to improve retinal function and delay AMD progression.

This is a prospective 2 center phase 2 clinical pilot study with no placebo group.

Conditions

  • Nonexudative Age-related Macular Degeneration

Interventions

DEVICE

Photobiomodulation (Gentlewaves, Warp 10)

Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.

Sponsors & Collaborators

  • Merry, Graham, M.D.

    lead INDIV

Principal Investigators

  • Graham F Merry, MBBS; LMCC · Dr. Graham Merry

  • Robert Dotson, M.D. · Dr. Robert Dotson

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00940407 on ClinicalTrials.gov